APA (7th ed.) Citation

Bieber, T., Katoh, N., Simpson, E. L., de Bruin-Weller, M., Thaçi, D., Torrelo, A., . . . Thyssen, J. P. (2023). Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: An updated integrated analysis of eight clinical trials. Journal of Dermatological Treatment, 34(1), 1. https://doi.org/10.1080/09546634.2022.2161812

Chicago Style (17th ed.) Citation

Bieber, Thomas, et al. "Safety of Baricitinib for the Treatment of Atopic Dermatitis over a Median of 1.6 Years and Up to 3.9 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials." Journal of Dermatological Treatment 34, no. 1 (2023): 1. https://doi.org/10.1080/09546634.2022.2161812.

MLA (9th ed.) Citation

Bieber, Thomas, et al. "Safety of Baricitinib for the Treatment of Atopic Dermatitis over a Median of 1.6 Years and Up to 3.9 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials." Journal of Dermatological Treatment, vol. 34, no. 1, 2023, p. 1, https://doi.org/10.1080/09546634.2022.2161812.